Tilia Fe
Product Images NDC 21695-685
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Tilia Fe (NDC 21695-685). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Rebel Distributors Corp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Mean Plasma Concentration Vs. Time (3cb9494c 4d70 4ebd 98ec 0e28021c1fee 02)
Mean Percent Reduction Vs. Cycle (3cb9494c 4d70 4ebd 98ec 0e28021c1fee 03)
This is a figure showing the mean percent reduction in total lesion counts from baseline to each 28-day cycle and the mean total lesion counts at each cycle following the administration of Norethindrone Acetate and Ethinyl Estradiol Tablets compared to a placebo. Statistically significant differences were not found in both studies individually until cycle 6. The graph shows a 100% reduction in lesion counts in the Norethindrone Acetate and Ethinyl Estradiol Tablets group and a 50% reduction in the placebo group. The data is based on an intent-to-treat population.*
Mortality Rates (3cb9494c 4d70 4ebd 98ec 0e28021c1fee 04)
Pill Pack Image (3cb9494c 4d70 4ebd 98ec 0e28021c1fee 05)
Pill Pack Image (3cb9494c 4d70 4ebd 98ec 0e28021c1fee 06)
Tilia Fe (3cb9494c 4d70 4ebd 98ec 0e28021c1fee 07)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.